Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TGZKY
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AMT-151
|
|||||
| Synonyms |
AMT-151
Click to Show/Hide
|
|||||
| Organization |
Multitude Therapeutics (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Ab-151
|
Antibody Info | ||||
| Antigen Name |
Folate receptor alpha (FOLR1)
|
Antigen Info | ||||
| Payload Name |
Duostatin 5
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Pip-Val-Cit linker
|
Linker Info | ||||
| Conjugate Type |
Reactive Lysines
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Breast cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Ovarian cancer |
1 Trials
|
||||||||
| Pancreatic cancer |
1 Trials
|
||||||||
| Pleura mesothelioma |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05498597 | Clinical Status | Phase 1 | ||
| Clinical Description | First-in-human, phase 1 study of AMT-151, an anti-folate receptor alpha antibody-drug conjugate, in patients with selected advanced solid tumours. | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Eligible patients (≥18 years) must have advanced ovarian, endometrial, lung, breast, pancreatic, or mesothelioma cancers that progressed after prior therapies, with measurable/non-measurable disease per RECIST 1.1, ECOG 0-1, and adequate organ function. Exclusions include prior Folate Receptor Alpha-targeted therapy, active CNS metastases, unresolved toxicities (>Grade 1), recent anticancer therapies/radiotherapy/surgery, transplant history, or significant comorbidities. WCBP require negative pregnancy tests.
Click to Show/Hide
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05498597 | Clinical Status | PHASE1 | ||
| Clinical Description | First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours | ||||
| Primary Endpoint |
The study evaluates the Recommended Phase 2 Dose (RP2D) and Maximum Tolerated Dose (MTD) based on dose-limiting toxicities (DLTs) over 24 months, alongside assessing safety through incidence of adverse events graded by CTCAE v5.0.
|
||||
| Other Endpoint |
Efficacy outcomes include Objective Response Rate (ORR), Disease Control Rate (DCR), Progression-Free Survival (PFS), Time to Treatment Response (TTR), Duration of Response (DoR), and Overall Survival (OS), along with pharmacokinetic parameters (Cmax, AUC, t1/2, Tmax) and anti-drug antibody (ADA) concentrations, all measured over 24 months.
|
||||
References